The treatment and prognosis analysis of KRAS single mutation and KRAS/TP53 co-mutation in lung adenocarcinoma

  • ZHANG Shanshan ,
  • LI Yumei ,
  • HUANG Zhuhua ,
  • BI Minghong
Expand
  • The First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China

Received date: 2023-08-13

  Online published: 2024-05-20

Abstract

Objective: To compare the treatment and prognosis of kirsten rat sarcoma viral oncogene (KRAS) mutant lung adenocarcinoma patients with different mutation states and molecular typing. Methods: The data of patients with advanced KRAS mutant lung adenocarcinoma who were diagnosed and received first-line therapy in the First Affiliated Hospital of Bengbu Medical College from April 2019 to April 2022 were collected. The co-mutation of TP53, molecular typing and the correlation of treatment prognosis were analyzed. Results: Follow-up to April 2022, the mPFS of patients with KRAS/TP53 co-mutation was significantly shorter than that of patients with KRAS single mutation (HR=0.613, 95%CI: 0.396-0.951, P=0.029), and the difference was statistically significant. The mPFS of chemotherapy combined with anti-angiogenesis therapy was significantly prolonger than that of chemotherapy alone (HR=0.593, 95%CI: 0.355-0.990, P=0.038). The mPFS of chemotherapy combined with immunotherapy group was significantly longer than that of chemotherapy alone (HR=0.426, 95%CI: 0.247-0.736, P=0.02). There was no significant difference in mPFS between chemotherapy combined with anti-angiogenesis therapy group and chemotherapy combined with immunotherapy group (HR=0.648, 95%CI: 0.371-1.130, P=0.126). Conclusion: TP53 is a poor prognostic factor in patients with advanced KRAS mutant lung adenocarcinoma. There is no significant difference in treatment and prognosis between different molecular subtypes of G12C and non-G12C. Chemotherapy combined with immunotherapy or anti-angiogenesis therapy can prolong PFS in patients with advanced lung adenocarcinoma compared with chemotherapy alone, but there is no significant difference in PFS between the combined treatment groups.

Cite this article

ZHANG Shanshan , LI Yumei , HUANG Zhuhua , BI Minghong . The treatment and prognosis analysis of KRAS single mutation and KRAS/TP53 co-mutation in lung adenocarcinoma[J]. Journal of Baotou Medical College, 2024 , 40(5) : 33 -38 . DOI: 10.16833/j.cnki.jbmc.2024.05.007

References

[1] Lee HJ, Jeong GH, Li H, et al. Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis[J]. Eur Rev Med Pharmacol Sci, 2021, 25(20): 6232-6244.
[2] Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)[J]. Lancet, 2016, 387(10026): 1415-1426.
[3] GhimessyA, Radeczky P, Laszlo V, et al. Current therapy of KRAS-mutant lung cancer[J]. Cancer Metastasis Rev, 2020, 39(4): 1159-1177.
[4] Remon J, Hendriks LE, Cabrera C, et al. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: is the time ripe for a change[J]. Cancer Treat Rev, 2018,71:47-58.
[5] O'Bryan JP. Pharmacological targeting of RAS: recent success with direct inhibitors[J]. Pharmacol Res, 2019, 139: 503-511.
[6] Shen M, Qi R, Ren J, et al. Characterization with KRAS mutant is a critical determinant in immunotherapy and other multiple therapies for non-small cell lung cancer[J]. Front Oncol, 2021, 11: 780655.
[7] Qin K, Hou HL, Liang Y, et al. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis[J]. BMC Cancer, 2020, 20(1): 328.
[8] La Fleur L, Falk-Sorqvist E, Smeds P, et al. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11[J]. Lung Cancer, 2019, 130: 50-58.
[9] Tomasint P, Mascaux C, Jao K, et al. Effect of coexisting KRAS and TP53 mutations in patients treated with chemotherapy for non-small-cell lung cancer[J]. Clin Lung Cancer, 2019, 20(3): e338-e345.
[10] Dong ZY, Zhong WZ, Zhang XC, et al. Potential predictive value of TP53 and KRASmutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma[J]. Clin Cancer Res, 2017, 23(12): 3012-3024.
[11] Arbour KC, Jordan E, Kim HR, et al. Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer[J]. Clin Cancer Res, 2018,24(2):334-340.
[12] Adderley H, Blackhall FH, Lindsayc R. KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition[J]. E Bio Medicine, 2019, 41: 711-716.
[13] Yang HT, Liang SQ, Schmid RA, et al. New horizons in KRAS-mutant lung cancer: dawn after darkness[J]. Front Oncol, 2019, 9: 953.
[14] Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis[J]. Br J Cancer, 2005, 92(1): 131-139.
[15] Villaruz LC, Socinski MA, Cunningham DE, et al. The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma[J]. Cancer, 2013, 119(12): 2268-2274.
[16] Fan GW, Zhang K, Ding JS, et al. Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis[J]. Oncotarget, 2017, 8(20): 33922-33932.
[17] Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma[J]. Cancer Discov, 2018, 8(7): 822-835.
[18] Shepherd FA, Lacas B, Le Teuff G, et al. Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy[J]. J Clin Oncol, 2017, 35(18): 2018-2027.
[19] Liu Y, Li H, Zhu J, et al. The prevalence and concurrent pathogenic mutations of KRASG12C in northeast Chinese non-small-cell lung cancer patients[J]. Cancer Manag Res, 2021, 13: 2447-2454.
[20] Luo JA, Ostrem J, Pellini B, et al. Overcoming KRAS-mutant lung cancer[J]. Am Soc Clin Oncol Educ Book, 2022(42): 700-710.
[21] Svaton M, Fiala O, Pesek M, et al. The prognostic role of KRAS mutation in patients with advanced NSCLC treated with second- or third-line chemotherapy[J]. Anticancer Res, 2016, 36(3): 1077-1082.
[22] Chen HX, Huang DZ, Lin G, et al. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer[J]. Cancer Med, 2022, 11(19): 3581-3592.
[23] Mellema WW, Masen-Poos L, Smit EF, et al. Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer[J]. Lung Cancer, 2015, 90(2): 249-254.
[24] D'incecco A, Andreozzi M, Ludovini V, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients[J]. Br J Cancer, 2015, 112(1): 95-102.
[25] Gettinger S, Horn L, Jackmand D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study[J]. J Clin Oncol, 2018, 36(17): 1675-1684.
Outlines

/